Changes in Staging and Management of Non-Small Cell Lung Cancer Screening at Kaohsiung Medical University Hospital

Since the U.S. National Lung Screening Trial (NLST) demonstrated the efficacy of low-dose computed tomography (LDCT) for early lung cancer detection, LDCT has emerged as a critical tool for identifying lung cancer in high-risk populations. This retrospective study evaluates trends in non-small cell lung cancer (NSCLC) staging at Kaohsiung Medical University Hospital (KMUH) from 2011 to 2020, with a particular focus on the effects of LDCT screening, which was introduced in 2013. We examined correlations between the number of LDCT screenings and NSCLC stage distribution, emphasizing early-stage (stages 0 and I) and late-stage (stage IV) diagnoses. Additionally, we assessed histopathological differences between adenocarcinoma and squamous cell carcinoma identified via LDCT and evaluated the impact of early diagnosis on five-year survival rates.